Exploring Breast Cancer Research at ESMO 2025 With Jasmin Hundal, MD, MS, MPH

Read the full interview on Oncology Data Advisor: https://oncdata.com/jasmin-hundal-esmo-breast-cancer At ESMO 2025, new data across early, metastatic, and HER2 positive breast cancer signaled important shifts in standards of care. In this interview, Editorial Board Member Jasmin Hundal, MD, MS, MPH, Hematology/Oncology Fellow at Cleveland Clinic, breaks down the most impactful trials and what they mean for real patients. Dr. Hundal reviews how monarchE and NATALEE are solidifying CDK4/6 inhibition in early HR positive disease, highlights emerging endocrine strategies such as giredestrant plus everolimus in ESR1 mutated metastatic tumors, and explains how DESTINY Breast trials are redefining the role of trastuzumab deruxtecan (T‑DXd) in HER2 positive cancer. She also emphasizes the importance of clear, patient centered communication when new data emerge before regulatory approval, helping patients understand that they received the best available options at the time while reassuring them that the treatment landscape is rapidly expanding. #BreastCancer #ESMO2025 #CDK46Inhibitors #monarchE #NATALEE #ESR1Mutations #SERDs #Giredestrant #HER2Positive #TDXd #DESTINYBreast #OncologyFellow #PrecisionOncology #OncologyDataAdvisor